Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Protagonist Therapeutics Inc (PTGX)

312 + Investors. Track Smart Money conviction in PTGX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
50%

Smart Money Signals — PTGX

Based on 314 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their PTGX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (99% of max)

99% of all-time peak
314 hedge funds hold PTGX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +16% more funds vs a year ago

fund count last 6Q
+44 new funds entered over the past year (+16% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 50% buying

165 buying164 selling
Last quarter: 165 funds bought or added vs 164 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-34 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 54 → 44 → 86 → 52. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 39% long-term, 29% new

■ 39% conviction (2yr+) ■ 32% medium ■ 29% new
Of the 314 current holders: 123 (39%) held >2 years, 101 held 1–2 years, and 90 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +20% but shares only +1% — price-driven

Value
+19%
Shares
+0%
Last quarter: the total dollar value of institutional holdings rose +20%, but actual share count only changed +1%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

69 → 54 → 44 → 86 → 52 new funds/Q
New funds entering each quarter: 54 → 44 → 86 → 52. A growing number of institutions are discovering PTGX each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 47% veterans vs 35% newcomers

■ 47% veterans ■ 19% 1-2yr ■ 35% new
Entry-cohort mix of 324 holders: 152 (47%) are 2+ year veterans, 60 entered 1–2 years ago, and 112 (35%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 45% AUM from top-100 funds

45% from top-100 AUM funds
53 of 309 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in PTGX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.0
out of 10
Moderate Exit Risk
Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — PTGX

In 2026 Q1, 165 hedge funds were net buyers of PTGX (52 opened a new position, 113 added to an existing one), while 164 reduced or exited (110 trimmed, 54 sold completely) — a 50% buyer ratio, indicating a slight buying edge. 45% of total institutional value in PTGX is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 314.

Hedge Fund Ownership: PTGX

How many hedge funds hold PTGX — quarterly history vs. share price
Quarterly hedge fund ownership of PTGX vs. share price

Market Analysis: PTGX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: PTGX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Protagonist Therapeutics Inc (PTGX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much PTGX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
PTGX
+4.2%
XLV
+4.9%

PTGX outperformed XLV by -0.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
PTGX
+7.4%
XLV
+6.0%

Since the filing became public, PTGX outperformed XLV by +1.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

23 top-rated funds 6 high-conviction
Consensus
6.0
/ 10
breadth
×
Elite
3.6
/ 10
conviction
Hedge Fund Positioning: PTGX
312 + Investors

Track Smart Money conviction in PTGX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 312 316 -1.27%
13F Shares 72M 72M 0.75%
Total Value $7.34B $6.12B 19.89%
New Positions 51 86 -35
Increased Positions 108 100 +8
Closed Positions 55 41 +14
Reduced Positions 107 100 +7
Total Calls 9 13 -30.77%
Total Puts 6 5 20.0%
PUT/CALL Ratio 0.67 0.38 Bullish

Statistics: PTGX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

312 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in PTGX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 PTGX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Johnson & Johnson 39.57% 2,449,183 $258.1M
2 NEXTBio Capital Management LP 11.24% 229,619 $24.2M
3 ADAR1 Capital Management, LLC 6.17% 994,119 $104.8M
4 Rtw Investments, LP 5.31% 5,059,053 $533.2M
5 Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 5.11% 571,825 $60.3M
6 KVP Capital Advisors, LP 4.17% 53,000 $5.6M
7 Knott David M Jr 3.95% 63,000 $6.6M
8 Farallon Capital Management LLC 3.81% 6,348,906 $669.2M
9 Eagle Health Investments LP 3.31% 179,322 $18.9M
10 Perceptive Advisors LLC 2.54% 1,230,879 $129.7M
11 Boxer Capital Management, LLC 2.35% 170,000 $17.9M
12 Birchview Capital, LP 2.10% 35,000 $3.7M
13 683 Capital Management, LLC 1.95% 355,000 $37.4M
14 NAN FUNG TRINITY (HK) Ltd 1.86% 160,670 $16.9M
15 Stempoint Capital LP 1.49% 72,577 $7.6M
16 Opaleye Management Inc. 1.39% 100,000 $10.5M
17 Elmind Capital, LP 1.14% 38,000 $4.0M
18 Moody Aldrich Partners LLC 1.02% 53,893 $5.7M
19 HighVista Strategies LLC 0.99% 33,852 $3.6M
20 Vestal Point Capital, LP 0.96% 326,159 $34.4M
21 AlphaCentric Advisors LLC 0.95% 9,040 $953K
22 Affinity Asset Advisors, LLC 0.94% 172,125 $18.1M
23 Hood River Capital Management LLC 0.88% 829,285 $87.4M
24 Arrowpoint Investment Partners (Singapore) Pte. Ltd. 0.87% 9,334 $984K
25 Atika Capital Management LLC 0.82% 62,100 $6.5M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Protagonist Therapeutics Inc (PTGX)

What does the Smart Money Trend signal show for PTGX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their PTGX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for PTGX?

Slight buying edge — 50% buying: Last quarter: 165 funds bought or added vs 164 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for PTGX holders?

Elite ownership — 45% AUM from top-100 funds: 53 of 309 holders are among the 100 largest funds by AUM, controlling 45% of total institutional value in PTGX. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held PTGX?

Mixed — 39% long-term, 29% new: Of the 314 current holders: 123 (39%) held >2 years, 101 held 1–2 years, and 90 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Protagonist Therapeutics Inc (PTGX) following the 2026 Q1 hedge fund 13F filings?

As of today, PTGX has moved +7.4% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of +1.4%. Since the quarter end (March 31, 2026), PTGX has gained +4.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →